Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study

Degludec is an ultralong-acting insulin analog with a flat and reproducible pharmacodynamic profile. As some patients with type 1 diabetes (T1D) fail to achieve 24-hour coverage with glargine or detemir despite twice-daily injections, we studied the effect of switching T1D patients from twice-daily glargine or detemir to degludec.

Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - August 5, 2016 Category: Nutrition Authors: S. Galasso, A. Facchinetti, B.M. Bonora, V. Mariano, F. Boscari, E. Cipponeri, A. Maran, A. Avogaro, G.P. Fadini, D. Bruttomesso Source Type: research